- Home
- INDV vs SNDX Comparison
INDV vs SNDX Comparison
Compare INDV & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INDV
- SNDX
- Stock Information
- Founded
- INDV 1994
- SNDX 2005
- Country
- INDV United States
- SNDX United States
- Employees
- INDV N/A
- SNDX N/A
- Industry
- INDV Biotechnology: Pharmaceutical Preparations
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- INDV Health Care
- SNDX Health Care
- Exchange
- INDV Nasdaq
- SNDX Nasdaq
- Market Cap
- INDV 1.2B
- SNDX 1.2B
- IPO Year
- INDV N/A
- SNDX 2016
- Fundamental
- Price
- INDV $8.45
- SNDX $16.38
- Analyst Decision
- INDV Strong Buy
- SNDX Strong Buy
- Analyst Count
- INDV 2
- SNDX 10
- Target Price
- INDV $16.00
- SNDX $36.20
- AVG Volume (30 Days)
- INDV 1.2M
- SNDX 2.5M
- Earning Date
- INDV 02-20-2025
- SNDX 03-04-2025
- Dividend Yield
- INDV N/A
- SNDX N/A
- EPS Growth
- INDV N/A
- SNDX N/A
- EPS
- INDV N/A
- SNDX N/A
- Revenue
- INDV $1,188,000,000.00
- SNDX $16,000,000.00
- Revenue This Year
- INDV $6.59
- SNDX N/A
- Revenue Next Year
- INDV N/A
- SNDX N/A
- P/E Ratio
- INDV N/A
- SNDX N/A
- Revenue Growth
- INDV 8.69
- SNDX N/A
- 52 Week Low
- INDV $7.33
- SNDX $12.06
- 52 Week High
- INDV $23.22
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- INDV 30.24
- SNDX 68.27
- Support Level
- INDV $9.74
- SNDX $14.53
- Resistance Level
- INDV $11.27
- SNDX $15.40
- Average True Range (ATR)
- INDV 0.51
- SNDX 0.70
- MACD
- INDV -0.18
- SNDX 0.13
- Stochastic Oscillator
- INDV 2.01
- SNDX 82.93
About INDV Indivior PLC
Indivior PLC is a specialty and generic drug manufacturing company. The company is focused on the development, manufacture, and sale of prescription drugs for treatment of substance use disorders and other serious mental illnesses. Its products include, Sublocade, Perseris, Suboxone, Opvee among others. The vast majority of Indivior's revenue is generated in the United States, followed by United Kingdom and the rest of the world.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.